Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
Engineered Salmonella secreting heterologous bacterial flagellin suppress tumor growth by activating intratumoral macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
From The microbiome and human cancer (2021) · cites this paper as [152]
Citations
Cites
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“INTRODUCTION Abnormal blood vessels and hypoxic and necrotic regions are universal features of solid tumors (1, 2).”
BackgroundKigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130 · cited 1×
“The engrafted MC38 tumor tissues were removed from C57BL/6 WT mice 24 hours after induction of FlaB and triple-stained with CD45, F4/80, and CD206 (to detect M2-type macrophages) or with CD45, F4/80, and CD86 (to detect M1-type macrophages) (32, 33).”
MethodTargeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041 · cited 1×
“TLR4, TLR5, and MyD88 knockout mice with a C57BL/6 genetic background were described previously (47, 48).”
MethodMolecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980 · cited 10×
“The in vitro stimulation of cancer cells with FlaB did not increase phosphorylation of NF-kB p65 (fig.”
BackgroundInfluentialThe Isolation and Characterization of Murine Macrophages
Zhang, X., Goncalves, R., & Mosser, D. M. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im1401s83 · Cited by 1,536 · cited 1×
“Cell preparation and FACS analysis Peritoneal macrophages were isolated from specific pathogen–free C57BL/6 male mice, as described previously (50).”
MethodToll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 1×
“Because the background signals in experimental groupswere different, whichmay be due to different degrees of cell injury resulting from the different modes of treatment (PBS, empty Salmonella, and FlaB-secreting Salmonella), we adjusted gating parameters for the FACS analysis of different groups (51, 52).”
MethodTherapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Because of accumulating reports that activating various TLRs resulted in antitumor effects (31, 37–41), many TLRspecific agonists are currently being investigated for tumor immunotherapy (37).”
BackgroundBiswas, S. K. (2006) · Blood · doi:10.1182/blood-2005-01-0428 · Cited by 696
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“VNP20009, an attenuated strainof Salmonella typhimurium with purI and msbB gene deletions, was safely administered to patients with metastatic melanoma and renal cell carcinoma in a phase 1 study, where substantial tumor colonization was observed (11, 12).”
Research works printed but not linked: 1
- 10.1200/jco.2002.20.1.142 · DOI · Paper page
Cited by
Molecular principles of metastasis: a hallmark of cancer revisited
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0134-x · Cited by 2,379
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“5B), with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
BackgroundThe microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
“reported development of a dual TLR4/5 stimulating bacterial cell therapy (BCT) based on attenuated ΔppGpp Salmonella typhimurium (TLR4 agonist) with inducible production of Vibrio vulnificus flagellin B (FlaB, TLR5 agonist) [167].”
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Metadata
- Authors
- Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., Choy, H. E., Lee, S. E., Rhee, J. H., & Min, J.-J.
- Affiliations
- Chonnam National University (KR)
- City Of Hope National Medical Center (US)
- Department of Nuclear Medicine, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Corresponding author
- Rhee, Joon Haeng
- Min, Jung-Joon
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-08
- Volume
- 9
- Issue
- 376
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2586223583
- Cited by
- 588
- References
- 54
- Citations by year
- 2026: 76 · 2025: 81 · 2024: 85 · 2023: 73 · 2022: 71 · 2021: 65 · 2020: 55 · 2019: 34 · 2018: 30 · 2017: 18
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- KRIBB Repository (submittedVersion)
- Funders
- Pioneer Research Center Program (2015M3C1A3056410)
- Bio & Medical Technology Development Program (NRF-2014M3A9B5073747)
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
- NRF (2012-0006072)
- Ministry of Health and Welfare, Republic of Korea (HI14C0187)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunotherapy, Salmonella typhimurium, tumor-targeting bacteria, intratumoral macrophages, M1 macrophage polarization, TLR ligands
- MeSH terms
- Animals, Colonic Neoplasms, Flagellin, Genetic Engineering, Humans, Immunotherapy, Macrophages, Male, Mice, Inbred C57BL, Mice, Nude, Neoplasm Metastasis, Neoplasms, Phenotype, Salmonella typhimurium, Colony Count, Microbial, Signal Transduction, Cell Polarity, Xenograft Model Antitumor Assays, HCT116 Cells, Toll-Like Receptor 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. https://app.cochat.ai/papers/10.1126/scitranslmed.aak9537
- The paper
- Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., Choy, H. E., Lee, S. E., Rhee, J. H., & Min, J.-J. (2017). Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aak9537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.